The role of auto-HSCT in extranodal natural killer/T cell lymphoma.

IF 1.7 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Open Medicine Pub Date : 2024-10-03 eCollection Date: 2024-01-01 DOI:10.1515/med-2024-1024

Yin-Yin Peng, Xin Wang, Lin Liu

{"title":"The role of auto-HSCT in extranodal natural killer/T cell lymphoma.","authors":"Yin-Yin Peng, Xin Wang, Lin Liu","doi":"10.1515/med-2024-1024","DOIUrl":null,"url":null,"abstract":"Objectives: Autologous hematopoietic stem cell transplantation (auto-HSCT) is considered optional consolidation therapy especially for relapsed/refractory extranodal NK/T-cell lymphoma (ENKL), but its applications to newly diagnosed advanced-stage ENKL is currently limited.Methods: We collected 51 cases of newly diagnosed advanced-stage ENKL patients, including 26 with auto-HSCT and 25 with chemotherapy rather than HSCT, from our hospital between 2014/01 and 2023/12. We summarized the patients' characteristics, conducted survival analysis of the 51 cases, and analyzed the potential benefits of auto-HSCT to ENKL patients.Results: It shows that after a median follow-up time of 39 months, the estimated 5-year overall survival (OS) of the 51 newly diagnosed advanced-stage ENKL patients is 73.4%, and their estimated 5-year progression-free survival (PFS) is 73.4%. For patients receiving auto-HSCT, the 5-year OS (91.7%) and PFS (91.0%) are significantly different from those of patients receiving chemotherapy without HSCT (OS 53.3%, PFS 54.5%) (p < 0.05). Univariate and multivariate analysis results suggest that only the l-asparaginase usage in chemotherapy showed significant impact on the OS, and none of concerned factors showed significant impact on the PFS.Conclusions: Auto-HSCT is indeed an option to newly diagnosed advanced-stage ENKL, but further studies are still required for more strict disease management.","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"19 1","pages":"20241024"},"PeriodicalIF":1.7000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459278/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/med-2024-1024","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Autologous hematopoietic stem cell transplantation (auto-HSCT) is considered optional consolidation therapy especially for relapsed/refractory extranodal NK/T-cell lymphoma (ENKL), but its applications to newly diagnosed advanced-stage ENKL is currently limited.

Methods: We collected 51 cases of newly diagnosed advanced-stage ENKL patients, including 26 with auto-HSCT and 25 with chemotherapy rather than HSCT, from our hospital between 2014/01 and 2023/12. We summarized the patients' characteristics, conducted survival analysis of the 51 cases, and analyzed the potential benefits of auto-HSCT to ENKL patients.

Results: It shows that after a median follow-up time of 39 months, the estimated 5-year overall survival (OS) of the 51 newly diagnosed advanced-stage ENKL patients is 73.4%, and their estimated 5-year progression-free survival (PFS) is 73.4%. For patients receiving auto-HSCT, the 5-year OS (91.7%) and PFS (91.0%) are significantly different from those of patients receiving chemotherapy without HSCT (OS 53.3%, PFS 54.5%) (p < 0.05). Univariate and multivariate analysis results suggest that only the l-asparaginase usage in chemotherapy showed significant impact on the OS, and none of concerned factors showed significant impact on the PFS.

Conclusions: Auto-HSCT is indeed an option to newly diagnosed advanced-stage ENKL, but further studies are still required for more strict disease management.

查看原文本刊更多论文

自体造血干细胞移植在结节外自然杀伤/T细胞淋巴瘤中的作用。

目的：自体造血干细胞移植（auto-HSCT）被认为是一种可选的巩固治疗方法，尤其适用于复发/难治性结外NK/T细胞淋巴瘤（ENKL），但其在新诊断的晚期ENKL中的应用目前还很有限：我们收集了本院2014/01至2023/12期间51例新确诊的晚期ENKL患者，其中26例接受了自体造血干细胞移植，25例接受了化疗而非造血干细胞移植。我们总结了患者的特征，对51例患者进行了生存分析，并分析了自体造血干细胞移植对ENKL患者的潜在益处：结果显示，在中位随访时间为39个月后，51例新确诊的晚期ENKL患者的估计5年总生存期（OS）为73.4%，估计5年无进展生存期（PFS）为73.4%。接受自体造血干细胞移植的患者的5年OS（91.7%）和PFS（91.0%）与未接受造血干细胞移植化疗的患者（OS 53.3%，PFS 54.5%）相比有显著差异（P < 0.05）。单变量和多变量分析结果表明，只有化疗中使用l-天冬酰胺酶对OS有明显影响，而相关因素对PFS均无明显影响：结论：对于新确诊的晚期ENKL，自体肝细胞移植确实是一种选择，但仍需进一步研究以进行更严格的疾病管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Medicine Medicine-General Medicine

CiteScore

3.00

自引率

0.00%

发文量

153

审稿时长

20 weeks

期刊介绍： Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The primary goal of the journal has always been a focus on maintaining the high quality of its published content. Its mission is to facilitate the exchange of ideas between medical science researchers from different countries. Papers connected to all fields of medicine and public health are welcomed. Open Medicine accepts submissions of research articles, reviews, case reports, letters to editor and book reviews.